Since Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) and RedHill Biopharma Ltd. (NASDAQ:RDHL) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation of both companies.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eiger BioPharmaceuticals Inc.	N/A	0.00	52.39M	-3.98	0.00
RedHill Biopharma Ltd.	8.36M	29.47	38.82M	-1.70	0.00

In table 1 we can see Eiger BioPharmaceuticals Inc. and RedHill Biopharma Ltd.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us Eiger BioPharmaceuticals Inc. and RedHill Biopharma Ltd.’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
Eiger BioPharmaceuticals Inc.	0.00%	-155.6%	-85.1%
RedHill Biopharma Ltd.	-464.35%	0%	0%

Analyst Recommendations

Recommendations and Ratings for Eiger BioPharmaceuticals Inc. and RedHill Biopharma Ltd. can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Eiger BioPharmaceuticals Inc.	0	0	0	0.00
RedHill Biopharma Ltd.	0	0	2	3.00

Competitively RedHill Biopharma Ltd. has a consensus price target of $16.5, with potential upside of 87.29%.

Insider and Institutional Ownership

Roughly 86.9% of Eiger BioPharmaceuticals Inc. shares are held by institutional investors while 29.11% of RedHill Biopharma Ltd. are owned by institutional investors. About 7.6% of Eiger BioPharmaceuticals Inc.’s share are held by insiders. Competitively, insiders own roughly 19.1% of RedHill Biopharma Ltd.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Eiger BioPharmaceuticals Inc.	2.07%	-1.07%	34.93%	7.63%	48.71%	36.12%
RedHill Biopharma Ltd.	-1.67%	-7.59%	-6.35%	2.68%	19.47%	38.2%

For the past year Eiger BioPharmaceuticals Inc. has weaker performance than RedHill Biopharma Ltd.

Summary

On 8 of the 10 factors RedHill Biopharma Ltd. beats Eiger BioPharmaceuticals Inc.

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. The company was founded in 2008 and is headquartered in Palo Alto, California.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company promotes two gastrointestinal products in the U.S., such as Donnatal, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; and EnteraGam, a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools. Its clinical-stage pipeline includes TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; RHB-104, an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status for nontuberculous mycobacteria infections; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron with successful top-line results in a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; YELIVA (ABC294640), a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory, and gastrointestinal indications; MESUPRON, a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors; and RIZAPORT (RHB-103), an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in two European Union member states under the European Decentralized Procedure. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.